NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Open in Screener

RZLT

Rezolute Inc

Jun 23 • 04:00PM ET

4.03

Dollar change -0.08
Percentage change -1.95	%

Healthcare • Biotechnology • USA • NASD

Peers: ASND KRYS SWTX LGND RAPT SVRA IMTX UBX RKDA

| Held by: VTI VXF IWC SBIO DFAS DFAC AVSC DFAU DCOR

Index	-	P/E	-	EPS (ttm)	-1.16	Insider Own	17.50%	Shs Outstand	86.81M	Perf Week	-4.05%
Market Cap	349.86M	Forward P/E	-	EPS next Y	-0.94	Insider Trans	20.01%	Shs Float	71.63M	Perf Month	0.50%
Enterprise Value	264.74M	PEG	-	EPS next Q	-0.21	Inst Own	51.10%	Short Float	6.18%	Perf Quarter	32.13%
Income	-73.00M	P/S	-	EPS this Y	30.96%	Inst Trans	4.03%	Short Ratio	3.94	Perf Half Y	-9.23%
Sales	0.00M	P/B	2.95	EPS next Y	-2.19%	ROA	-80.01%	Short Interest	4.43M	Perf YTD	-17.76%
Book/sh	1.36	P/C	4.03	EPS next 5Y	12.97%	ROE	-95.15%	52W High	6.19 -34.85%	Perf Year	3.87%
Cash/sh	1.00	P/FCF	-	EPS past 3/5Y	21.26% 40.87%	ROIC	-87.18%	52W Low	2.21 81.94%	Perf 3Y	27.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.54% 2.99%	Perf 5Y	-34.44%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-1.69%	Oper. Margin	-	ATR (14)	0.26	Perf 10Y	-98.32%
Dividend Ex-Date	-	Quick Ratio	8.43	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.38	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.43	EPS Q/Q	19.52%	SMA20	-3.96%	Beta	1.04	Target Price	13.11
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	6.39%	Rel Volume	0.58	Prev Close	4.11
Employees	59	LT Debt/Eq	0.01	Earnings	May 13 AMC	SMA200	-9.02%	Avg Volume	1.13M	Price	4.03
IPO	May 08, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.06% -	Trades		Volume	651,406	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-24	Initiated	Wedbush	Outperform	$12
Aug-27-24	Initiated	Guggenheim	Buy	$11
Jul-17-24	Initiated	BTIG Research	Buy	$13
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

May-28-25 08:00AM	Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism (GlobeNewswire)
May-20-25 12:08PM	Rezolute, Inc. (RZLT): Analysts See 260% Upside Potential (Insider Monkey)
May-13-25 04:05PM	Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-05-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
May-01-25 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.32%
03:57AM	Loading…
03:57AM	Rezolute: RZ402 Could Be A Surprise Candidate In The Making (Seeking Alpha)
Apr-25-25 04:30PM	Rezolute, Inc. Announces Closing of Underwritten Offering (GlobeNewswire)
Apr-23-25 08:05AM	Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) +27.65%
08:00AM	Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ( HI ) (GlobeNewswire)
Apr-11-25 12:00PM	Rezolute (RZLT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-26-25 07:30AM	Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors (GlobeNewswire) -5.54%
Feb-12-25 04:05PM	Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-04-25 08:00AM	Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Jan-31-25 08:00AM	Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-07-25 08:00AM	Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
08:00AM	Loading…
Dec-05-24 08:00AM	Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 08:00AM	FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Nov-07-24 04:05PM	Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-19-24 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire) +5.39%
Sep-09-24 07:30AM	FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study (GlobeNewswire) +22.07%
Aug-27-24 08:00AM	Rezolute to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-05-24 07:30AM	Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism (GlobeNewswire)
Jul-31-24 08:00AM	Rezolute to Participate in the BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-27-24 08:00AM	Rezolute Announces Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire)
Jun-24-24 08:00AM	Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds (GlobeNewswire) +7.85%
Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
07:23AM	Loading…
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire) +13.76%
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22% -7.39%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire) +6.15%
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)
09:33AM	Rezolute, Inc. Announces Closing of Registered Direct Offering (GlobeNewswire)
May-01-22 11:25PM	Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (GlobeNewswire)
02:00PM	Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism (GlobeNewswire)
Apr-26-22 04:05PM	RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 (GlobeNewswire) -7.74% +5.06%
Mar-29-22 07:00AM	Rezolute Joins the Rare Disease Company Coalition (GlobeNewswire) -8.72%
Mar-23-22 07:00AM	Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +7.34%
Feb-22-22 07:00AM	Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME (GlobeNewswire) -6.18%
Feb-09-22 04:05PM	Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
Nov-12-21 04:05PM	Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? (Simply Wall St.)
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering (GlobeNewswire) -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering (GlobeNewswire)
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 (GlobeNewswire)
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -8.69%
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism (GlobeNewswire) +7.00%
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME (GlobeNewswire) +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index (GlobeNewswire)
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead (TipRanks) +25.12%
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? (Simply Wall St.)
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential (TipRanks)
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs (GlobeNewswire)
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board (GlobeNewswire)
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit (GlobeNewswire)
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema (GlobeNewswire)
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners (GlobeNewswire)
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 (GlobeNewswire)
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts (GlobeNewswire) +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March (GlobeNewswire) -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results (GlobeNewswire) -9.07% +5.51%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema (GlobeNewswire) +6.84%

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its clinical assets include Ersodetug, a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism, and RZ402, an oral plasma kallikrein inhibitor and potential therapy for the chronic treatment of diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23 09:38 AM
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23 09:12 AM
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01 03:52 PM
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31 09:18 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.89	10,000	28,900	237,900	Mar 28 08:40 AM
Evans Daron	CFO	Mar 26 '25	Buy	2.88	10,000	28,800	23,000	Mar 28 08:40 AM
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20 07:59 PM
Kim Young-Jin	Director	Jun 25 '24	Buy	4.00	1,250,000	5,000,000	7,192,617	Feb 19 09:16 PM
Evans Daron	CFO	Dec 18 '24	Buy	4.29	10,000	42,900	150,900	Dec 18 06:01 PM
Evans Daron	CFO	Dec 12 '24	Buy	4.60	9,000	41,400	140,900	Dec 12 04:54 PM
Evans Daron	CFO	Dec 09 '25	Buy	5.04	10,549	53,167	131,900	Dec 10 09:11 AM
Hogenhuis Wladimir	Director	Sep 24 '24	Buy	4.70	4,259	20,017	41,767	Sep 24 05:14 PM
Hogenhuis Wladimir	Director	Jun 25 '24	Buy	4.15	4,815	19,982	37,508	Jun 27 02:00 PM

TRDA Entrada Therapeutics Inc daily Stock Chart

Peers: MRNA REGN PFE GILD BNTX NVAX VRTX SRPT INCY RNA

| Held by: VTI IWM VXF IWN IBB VTWO SCHA FDM VHT AVSC

Index	RUT	P/E	8.71	EPS (ttm)	0.81	Insider Own	41.48%	Shs Outstand	37.94M	Perf Week	-7.25%
Market Cap	267.19M	Forward P/E	-	EPS next Y	-4.25	Insider Trans	-0.01%	Shs Float	22.21M	Perf Month	-8.45%
Enterprise Value	-58.32M	PEG	-	EPS next Q	-0.85	Inst Own	52.90%	Short Float	4.92%	Perf Quarter	-32.89%
Income	24.78M	P/S	1.55	EPS this Y	-288.17%	Inst Trans	-2.08%	Short Ratio	7.54	Perf Half Y	-61.84%
Sales	172.22M	P/B	0.64	EPS next Y	-34.37%	ROA	4.97%	Short Interest	1.09M	Perf YTD	-59.28%
Book/sh	11.00	P/C	0.70	EPS next 5Y	-	ROE	7.22%	52W High	21.79 -67.69%	Perf Year	-52.40%
Cash/sh	10.08	P/FCF	-	EPS past 3/5Y	- -	ROIC	5.30%	52W Low	6.94 1.44%	Perf 3Y	-23.23%
Dividend Est.	-	EV/EBITDA	-7.43	Sales past 3/5Y	- -	Gross Margin	97.83%	Volatility	1.85% 2.94%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-0.34	EPS Y/Y TTM	24.45%	Oper. Margin	2.39%	ATR (14)	0.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	21.88	Sales Y/Y TTM	5.74%	Profit Margin	14.39%	RSI (14)	35.16	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	21.88	EPS Q/Q	-162.54%	SMA20	-9.01%	Beta	-0.06	Target Price	20.50
Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	-65.23%	SMA50	-13.41%	Rel Volume	0.61	Prev Close	7.12
Employees	183	LT Debt/Eq	0.12	Earnings	May 08 BMO	SMA200	-47.00%	Avg Volume	144.94K	Price	7.04
IPO	Oct 29, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	46.74% 102.12%	Trades		Volume	88,591	Change	-1.12%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	ROTH MKM	Buy	$29
Jan-05-24	Initiated	Oppenheimer	Outperform	$22
Apr-03-23	Initiated	H.C. Wainwright	Buy	$25

Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
Jun-02-25 04:30PM	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.11%
May-29-25 11:10AM	Entradas Phase I/II trial of DMD treatment authorised to begin in EU (Clinical Trials Arena)
May-28-25 07:00AM	Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
May-08-25 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +5.64%
07:00AM	Loading…
07:00AM	Entrada Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 10:01AM	Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release (Zacks)
08:00AM	Arvinas, Entrada cut staff; Merck builds US hub for Keytruda (BioPharma Dive)
Apr-29-25 10:01AM	Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-10-25 09:30AM	Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock? (Zacks) -5.08%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
Mar-25-25 10:03AM	Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment (Clinical Trials Arena) -5.79%
Mar-24-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping (GlobeNewswire)
Feb-27-25 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
06:11AM	Loading…
Feb-26-25 06:11AM	AstraZenecas next breast cancer drug; Madrigals accelerating MASH launch (BioPharma Dive)
Feb-25-25 01:05PM	FDA removes clinical hold on Entradas Duchenne therapy (Clinical Trials Arena) -5.68%
Feb-24-25 07:00AM	Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 (GlobeNewswire)
Feb-12-25 07:58AM	Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-04-25 07:19AM	Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment (Clinical Trials Arena)
Feb-03-25 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy (GlobeNewswire)
Jan-30-25 04:05PM	Azenta Announces the Election of Dipal Doshi to its Board of Directors (PR Newswire)
Dec-18-24 07:00AM	Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.32%
Dec-07-24 05:25AM	Roth MKM starts overlooked Entrada Therapeutics with Buy rating (TipRanks)
Nov-25-24 08:50AM	Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Nov-05-24 08:15AM	Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Entrada Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-09-24 07:00AM	Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society (GlobeNewswire)
Sep-24-24 07:00AM	Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development (GlobeNewswire) +5.70%
Sep-17-24 08:30AM	ashibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors (Business Wire)
07:00AM	Loading…
Sep-06-24 07:00AM	Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program (GlobeNewswire)
Aug-13-24 08:20AM	Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates (Zacks) +11.26%
07:00AM	Entrada Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-25-24 09:55AM	Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High? (Zacks) +5.75%
Jul-12-24 09:33AM	Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last? (Zacks)
Jun-24-24 07:15AM	Entrada Therapeutics Announces $100 Million Registered Direct Offering (GlobeNewswire)
06:00AM	Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-03-24 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-21-24 09:55AM	Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet (Zacks)
May-20-24 05:32PM	Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing (MT Newswires)
May-16-24 07:02PM	Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
04:35PM	Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing (MT Newswires)
07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-07-24 01:53PM	TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Entrada Therapeutics Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-10-24 03:29PM	Insiders are Piling into These 5 Healthcare Stocks in 2024 (Insider Monkey) -5.72%
Apr-04-24 02:00PM	The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. (PR Newswire)
Mar-27-24 01:27AM	Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA) (GuruFocus.com)
Mar-15-24 05:31AM	Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials (GuruFocus.com)
Mar-13-24 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +9.76%
Feb-07-24 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-29-24 08:14AM	Time to Pull the Trigger, Says Oppenheimer About These 3 Stocks (TipRanks)
Jan-03-24 07:00AM	Entrada Therapeutics Promotes Nathan J. Dowden to President (GlobeNewswire) -9.03%
Dec-28-23 07:01AM	Entrada Therapeutics Inc CFO Kory Wentworth Sells 12,500 Shares (GuruFocus.com)
Nov-23-23 11:47AM	Entrada (TRDA) Down on FDA Maintaining Clinical Hold on DMD Drug (Zacks)
Nov-22-23 07:00AM	Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -31.85%
Nov-07-23 08:25AM	Entrada Therapeutics, Inc. (TRDA) Surpasses Q3 Earnings and Revenue Estimates (Zacks) +8.63%
08:06AM	Entrada Therapeutics Inc (TRDA) Reports Q3 2023 Earnings, Net Income of $35.5 Million (GuruFocus.com)
07:00AM	Entrada Therapeutics Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-12-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -9.47%
Sep-21-23 07:00AM	Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-16-23 01:01AM	Insider Sell: Entrada Therapeutics Inc CEO Dipal Doshi Sells 1,000 Shares (GuruFocus.com)
Sep-07-23 07:00AM	Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community (GlobeNewswire) +5.48%
Aug-29-23 07:00AM	Entrada Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Entrada Therapeutics Appoints Gina Chapman to its Board of Directors (GlobeNewswire)
Aug-08-23 08:40AM	Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +10.47%
07:00AM	Entrada Therapeutics Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-04-23 06:36AM	Entrada Therapeutics (NASDAQ:TRDA) pulls back 16% this week, but still delivers shareholders notable 33% return over 1 year (Simply Wall St.)
Aug-01-23 07:00AM	Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-21-23 06:43AM	New Strong Buy Stocks for July 21st (Zacks)
Jun-06-23 07:00AM	Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire) +6.54%
May-15-23 06:03AM	Some Analysts Just Cut Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Estimates (Simply Wall St.)
May-13-23 08:03AM	Entrada Therapeutics, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now (Simply Wall St.)
May-10-23 07:00AM	Entrada Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-30-23 10:26AM	We Think Entrada Therapeutics (NASDAQ:TRDA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Apr-04-23 07:00AM	Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors (GlobeNewswire) -5.07%
Mar-29-23 07:00AM	Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference (GlobeNewswire)
Mar-08-23 06:02AM	Entrada Therapeutics, Inc. (NASDAQ:TRDA) Is About To Turn The Corner (Simply Wall St.) +5.94%
Mar-06-23 07:00AM	Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 07:00AM	Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-09-23 07:00AM	Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
Jan-09-23 07:00AM	Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable (GlobeNewswire) +6.95%
Dec-22-22 08:07AM	Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More (Zacks) -5.30%
Dec-20-22 10:03AM	Entrada (TRDA) Down on Regulatory Update for DMD Candidate (Zacks) -19.76%
Dec-19-22 04:30PM	Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy (GlobeNewswire) -6.09%
Dec-14-22 10:24AM	Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More (Zacks)
Dec-09-22 01:41PM	Entrada (TRDA) Surges on Collaboration With Vertex for DMI (Zacks) -9.19%
Dec-08-22 04:12PM	Entrada Skyrockets On $250 Million Deal With Vertex In Muscular Dystrophy (Investor's Business Daily) +18.51%
10:58AM	Entrada Therapeutics Stock Gains On Licensing Pact With Vertex For Form Of Neuromuscular Disorder (Benzinga)
08:24AM	Entrada Therapeutics shares jump on collaboration with Vertex (MarketWatch)
07:00AM	Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1) (Business Wire)
Nov-22-22 07:00AM	Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-07-22 07:00AM	Entrada Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -10.02%
Aug-30-22 07:00AM	Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-11-22 07:00AM	Entrada Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 07:00AM	Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jul-19-22 07:00AM	Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer (GlobeNewswire) +8.81%
Jul-14-22 10:47AM	We're Hopeful That Entrada Therapeutics (NASDAQ:TRDA) Will Use Its Cash Wisely (Simply Wall St.)
Jul-06-22 07:00AM	Entrada Therapeutics to Present at William Blair Biotech Focus Conference (GlobeNewswire)
Jun-01-22 07:00AM	Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference (GlobeNewswire) -15.24%

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding a pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in 2016 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WENTWORTH KORY JAMES	Chief Financial Officer	Apr 03 '25	Option Exercise	2.10	11,134	23,381	120,670	Apr 04 04:34 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Mar 17 '25	Sale	10.67	1,784	19,035	109,536	Mar 19 04:32 PM
KORY WENTWORTH	Officer	Mar 17 '25	Proposed Sale	10.81	1,784	19,285		Mar 17 04:32 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BIOVENTURES 2018, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 10 '24	Sale	20.77	22,935	476,360	4,402,849	Dec 12 05:00 PM
MPM BioVentures 2014, L.P.	10% Owner	Dec 11 '24	Sale	20.23	21,787	440,751	4,381,062	Dec 12 05:00 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Option Exercise	2.10	5,000	10,500	78,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Option Exercise	2.10	1,000	2,100	74,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Dec 02 '24	Sale	20.00	5,000	99,978	73,849	Dec 03 05:26 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 29 '24	Sale	19.97	1,000	19,970	73,849	Dec 03 05:26 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 03 '24	Sale	20.15	11,703	235,786	144,997	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Dec 02 '24	Sale	20.26	4,088	82,834	156,700	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 29 '24	Sale	20.00	100	2,000	160,788	Dec 03 05:24 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 13 '24	Sale	20.04	2,700	54,109	160,888	Nov 13 04:49 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 11 '24	Sale	20.01	1,409	28,191	163,588	Nov 13 04:49 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Option Exercise	2.10	6,000	12,600	82,486	Nov 13 04:47 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Nov 11 '24	Sale	19.98	8,637	172,562	73,849	Nov 13 04:47 PM
NATARAJAN SETHURAMAN	Officer	Nov 11 '24	Proposed Sale	19.82	18,762	371,863		Nov 12 07:54 AM
KORY WENTWORTH	Officer	Nov 11 '24	Proposed Sale	19.82	14,637	290,105		Nov 12 07:53 AM
Sethuraman Natarajan	President, Research & Develop.	Nov 06 '24	Sale	18.85	12,299	231,776	164,997	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 05 '24	Sale	18.18	5,171	94,006	177,296	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Nov 04 '24	Sale	18.02	749	13,498	182,467	Nov 06 04:36 PM
Sethuraman Natarajan	President, Research & Develop.	Oct 16 '24	Sale	18.00	600	10,800	183,216	Oct 18 04:31 PM
NATARAJAN SETHURAMAN	Officer	Oct 16 '24	Proposed Sale	17.53	20,057	351,599		Oct 16 04:25 PM
Dowden Nathan J	President & COO	Sep 26 '24	Sale	16.00	847	13,552	125,149	Sep 30 04:32 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Sep 09 '24	Sale	14.97	3,195	47,832	76,486	Sep 10 04:34 PM
Dowden Nathan J	President & COO	Sep 09 '24	Sale	15.07	1,904	28,690	125,996	Sep 10 04:33 PM
Dowden Nathan J	President & COO	Sep 06 '24	Sale	15.19	399	6,063	127,900	Sep 10 04:33 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 09 '24	Sale	15.09	2,642	39,862	183,816	Sep 10 04:32 PM
Sethuraman Natarajan	Chief Scientific Officer	Sep 06 '24	Sale	15.24	600	9,141	186,458	Sep 10 04:32 PM
KORY WENTWORTH	Officer	Sep 09 '24	Proposed Sale	14.80	3,195	47,286		Sep 09 04:27 PM
NATHAN DOWDEN	Officer	Sep 06 '24	Proposed Sale	15.39	3,150	48,478		Sep 06 04:19 PM
Dowden Nathan J	President & COO	Aug 16 '24	Option Exercise	1.74	20,000	34,800	157,204	Aug 20 04:33 PM
Dowden Nathan J	President & COO	Aug 16 '24	Sale	16.27	27,097	440,801	130,107	Aug 20 04:33 PM
NATHAN DOWDEN	Officer	Aug 16 '24	Proposed Sale	16.26	27,097	440,597		Aug 16 04:25 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 15 '24	Sale	18.00	638	11,484	188,814	Jul 16 04:43 PM
Sethuraman Natarajan	Chief Scientific Officer	Jul 12 '24	Sale	18.00	600	10,800	189,452	Jul 16 04:43 PM
Doshi Dipal	CEO	Jul 15 '24	Sale	17.81	1,600	28,497	334,475	Jul 16 04:42 PM
Doshi Dipal	CEO	Jul 12 '24	Sale	18.00	300	5,400	336,075	Jul 16 04:42 PM
WENTWORTH KORY JAMES	Chief Financial Officer	Jul 08 '24	Sale	14.95	1,758	26,282	81,412	Jul 10 04:34 PM

RZLT

Rezolute Inc

TRDA

Entrada Therapeutics Inc

Upgrade your FINVIZ experience